Abstract
The understanding of the immunobiology of infections caused by the protozoan parasite leishmania is now extensive and has pinpointed the importance of T cell-mediated immunity. Several vaccination strategies using either killed parasites, subunit vaccines, DNA vaccines or live attenuated strains have been used successfully with and without adjuvants to induce cellular immunity and protect against leishmania infections. The most recent progress in leishmania vaccine development is described.